Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Patupilone in NSCLC Brain Metastases
NCT00219297Phase 2Completed
- Sponsor
- Novartis
- Start
- Nov 2005
- Primary completion
- Jun 2010
- Modality
- Covalent Small Molecules, RNA-Targeting Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of patupilone in non-small cell lung cancer (NSCLC) and brain metastases, sponsored by Novartis. Primary endpoint: Tumor response as assessed by radiologic techniques and/or physical examination based on Response Evaluation Criteria in Solid Tumors (RECIST). Started Nov 2005; status: completed.
02
Drugs
patupilone
03
Conditions
non-small cell lung cancer (NSCLC)brain metastases
Beyond the preview
Go deeper on NCT00219297.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00219297.